Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies


Illumina, Inc. (NASDAQ: ILMN) today announced that the U.S. District Court for the Northern District of California issued a preliminary injunction order against several BGI companies, including MGI Tech Co., Ltd., Complete Genomics Inc., BGI Americas Corp., and MGI Americas Inc. The preliminary injunction was granted in two patent infringement lawsuits that Illumina filed against BGI in June 2019 (Case No. 3:19-cv-03770) and February 2020 (Case No. 3:20-cv-01465).

The preliminary injunction order prohibits BGI from launching its sequencing instruments and related reagents in the United States. The order prohibits the supply, use or sale of both the standard and “CoolMPS” chemistries.

“We are pleased with the Court’s decision. It validates that BGI has blatantly copied Illumina’s proprietary sequencing chemistry,” said Charles Dadswell, SVP and General Counsel for Illumina. “Illumina’s patents reflect the hard work, dedication and investment made by Illumina and its scientists, revolutionizing the industry and dramatically driving down the cost of sequencing.”

The preliminary injunction is based on U.S. Patent Nos. 7,541,444; 7,566,537; 7,771,973; 9,410,200; and 10,480,025. The patents cover Illumina’s proprietary sequencing-by-synthesis chemistry. Related patent suits are pending in Denmark, Finland, Germany, Sweden, Switzerland, Turkey, and the UK. The trial in the US case is scheduled to begin on May 25, 2021.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005978/en/

Illumina Inc. Stock

€114.08
-0.590%
The price for the Illumina Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.680 (-0.590%).
Currently there is a rather positive sentiment for Illumina Inc. with 18 Buy predictions and 4 Sell predictions.
With a target price of 183 € there is a hugely positive potential of 60.41% for Illumina Inc. compared to the current price of 114.08 €.
Like: 0
Share
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments